PIK3CA and non-small cell lung carcinoma: A Phase Ib trial investigated the combination therapy of gefitinib and the oral class I PI3K inhibitor BKM120 in patients with advanced NSCLC, focusing on those with alterations in PI3K pathway molecules and known overexpression of EGFR (NCT01570296) (National Cancer Centre, Singapore, 2012).